A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis

NCT03725007 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

124

Enrollment

INDUSTRY

Sponsor class

Conditions

Juvenile Idiopathic Arthritis (JIA)

Interventions

DRUG: Upadacitinib

Sponsor

AbbVie